Marissa Katherine Shoji

Marissa Shoji practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Marissa Shoji's NPI, 1265096929, was assigned on April 29, 2019. Marissa Shoji graduated from Harvard Medical School in 2019. Marissa Shoji holds California license A186026.

Marissa Shoji's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Marissa Shoji's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Marissa Shoji is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Marissa Shoji to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Marissa Shoji practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Marissa Shoji's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Marissa Shoji is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Marissa Shoji's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists conjunctivitis and eyelid inflammation among the conditions Marissa Shoji treats.

CMS data shows 60 Medicare services from Marissa Shoji across 2 procedure codes in 2024, all of them office visits, for 72 Medicare patients. Medicare paid $4,871 for them. Every service was in an office.

CMS counts 72 Medicare patients who saw Marissa Shoji in 2024. The largest group is 65 to 74, with 29 patients. 72% of them have high blood pressure, and 72% have high cholesterol. 33% are also on Medicaid. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Marissa Shoji's median patient age at 63, with 66% women.

In 2024, Marissa Shoji wrote 230 Medicare Part D claims for 123 patients. 66% of them were for generic drugs. CMS names the drug for 174 of them, across 6 drugs with 11 or more claims each, at $6,095 in total drug cost. In 2023, CMS named 573 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Marissa Shoji for performance year 2024, reported as part of a group. Marissa Shoji accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 51 papers to Marissa Shoji, published from 2017 to 2025. 2023 was the busiest year, with 12. The most frequent topics are Eyelids, Glaucoma, Open-Angle and Intraocular Pressure. Marissa Shoji has published most often in Ophthalmic Plast Reconstr Surg. Marissa Shoji's most frequent co-authors are Don O. Kikkawa, MD, Sander R. Dubovy, MD and Bobby S. Korn, MD.

CMS Open Payments shows 28 general payments to Marissa Shoji from 9 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $816.

Marissa Shoji graduated from Harvard Medical School in 2019.

Marissa Shoji is in network with 10 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.